Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Clinical trial NCT01847664 · COMPLETED

Trial details

NCT number: NCT01847664
Sponsor: Dr. Falk Pharma GmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Uncomplicated Diverticulitis

Start date: 2013-08-01
Primary completion: 2017-07-01
Enrollment: 204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.